What Adenocor Treats: Main Uses and Benefits

Adenocor (adenosine) is a medication utilized primarily in a clinical setting to address acute episodes of an abnormally fast heart rate originating above the ventricles, known as paroxysmal supraventricular tachycardia (PSVT).

Its main purpose is the rapid termination of this specific rhythm disturbance. The medication operates by temporarily slowing electrical conduction through the heart's atrioventricular (AV) node. This action helps to interrupt the re-entry circuit that sustains the rapid heart rate, thereby promoting the restoration of a normal heart rhythm (sinus rhythm).

A key benefit of this therapeutic approach is its ultra-short duration of action, which minimizes systemic exposure and allows for a rapid effect and resolution. The use of adenosine in this context is a standard medical procedure for acute rhythm management.

Regulatory References

1. NIH MedlinePlus guidance on adenosine injection

Eligibility Map: Who can and cannot use Adenocor

Official regulatory documentation defines the eligible patient population for Adenocor (Adenosine) Injection based on specific cardiac, pulmonary, and age-related criteria.

---

Category	Official Regulatory Statement
Populations for whom use is contraindicated	Second- or Third-Degree AV Block or Sick Sinus Syndrome (unless a functioning artificial pacemaker is present). Known or Suspected Bronchospastic Lung Disease (e.g., asthma). Long QT Syndrome or Severe Hypotension [1.1, 1.6, 2.6].
Age-Related Eligibility Rules	Pediatric Population (Under 18): Safety and effectiveness have not been established [1.3, 2.3]. Geriatric Population: Use is with caution due to potential for diminished cardiac function [1.2].
Condition-Specific Rules	Renal and Hepatic Impairment: No dosage adjustment or restriction is needed, as the drug is not dependent on these organs for metabolism [3.1]. Unstable Angina: Avoid use during pharmacologic stress testing [1.5].
Pregnancy and Lactation Status	Pregnancy: Classified as Category C; use only if clearly needed [1.2, 2.3]. Lactation: Decision to interrupt nursing or discontinue the drug is necessary due to potential risk to the infant [2.1].

---

Eligibility Classifications

Official documents classify population risks as Contraindicated (absolute prohibition), Avoid use (strong restriction in specific contexts), and Use with Caution (conditional use in populations with pre-existing minor conduction defects or certain hemodynamic risks) [1.5, 1.6]. The overall eligibility profile is structured by these classifications to ensure only adult patients without specific nodal or pulmonary exclusions receive the medication [1.2].

Interactions with other medicines and products

Adenocor (adenosine) interacts with specific classes of medicinal products, which can lead to either reduced or enhanced effects. These interactions are officially documented in regulatory information and require careful management.

---

Documented Interacting Product Categories

Interacting Product Category	Effect on Adenocor	Practical Implication
Methylxanthines (e.g., Theophylline, Caffeine, Aminophylline)	Antagonism (Inhibit/Reduce effect)	These agents compete with adenosine, potentially diminishing its required effect. Whenever feasible, these drugs should be withheld for a defined period (at least five half-lives) before using Adenocor.
Nucleoside Transport Inhibitors (e.g., Dipyridamole)	Potentiation (Enhance/Increase effect)	These agents can significantly increase the desired effect of adenosine. Whenever feasible, these drugs should be withheld for a defined period (at least five half-lives) before using Adenocor.
Cardioactive Drugs (e.g., Beta-blockers, Cardiac Glycosides, Calcium Channel Blockers)	Potential for Additive Depressant Effects	Use with caution, as co-administration may result in additive or synergistic depressant effects on the heart's electrical nodes (SA and AV nodes).

---

The regulatory profile clearly outlines these specific interactions. The primary management constraint involves the required pre-procedural discontinuation of drugs that either inhibit or augment Adenocor’s action. Additionally, caution is advised when co-administering drugs that share similar depressant effects on cardiac conduction, reflecting the official constraints necessary to ensure predictable outcomes.

The mechanism of action for Adenocor (adenosine) involves interaction with specific purinergic receptors. Adenosine is an endogenous nucleoside that acts as a potent agonist at G-protein coupled A1 adenosine receptors, which are highly concentrated in the sinoatrial (SA) and atrioventricular (AV) nodes of the cardiac conduction system.

Activation of the A1 receptor initiates a downstream cascade mediated by the inhibitory Gi protein. This Gi protein, when unbound, inhibits adenylyl cyclase, resulting in a decrease in the intracellular concentration of cyclic adenosine monophosphate (cAMP). The subsequent reduction in cAMP concentration leads to the closure of L-type calcium channels and the opening of IK,ACh (acetylcholine-sensitive inward rectifier potassium) channels. The efflux of potassium ions hyperpolarizes the cell membrane, prolonging the effective refractory period, particularly within the AV node.

This electrophysiological modification causes a transient, dose-dependent decrease in the rate of SA node discharge and a marked reduction in conduction velocity through the AV node, leading to a temporary block of impulse transmission. The system-level physiological consequence is a highly transient, controlled slowing of the cardiac rhythm due to the localized disruption of the normal cardiac electrical signaling pathway.

How to Use Adenocor (Adenosine) Injection

Adenocor (adenosine) is administered exclusively via the intravenous (IV) route and is intended for use only in a hospital setting where facilities for continuous cardiac monitoring and cardiopulmonary resuscitation equipment are immediately available. The drug is supplied as a 3 mg/mL solution for injection and must be visually inspected for particulate matter or discoloration before any administration.

---

Administration Protocols and Dosing

1. For Acute Termination of PSVT: Administration involves a standardized, step-wise rapid IV bolus sequence. The initial dose is 3 mg injected over one to two seconds. If the first dose is ineffective after 1–2 minutes, the second dose is 6 mg. If the arrhythmia persists, the final dose is 12 mg. No additional or higher doses are recommended.

Crucially, this rapid bolus must be immediately followed by a rapid saline flush to ensure the dose reaches the central circulation quickly, and the injection should occur into the most proximal vein or IV port available.

2. For Pharmacologic Stress Testing (MPS): In this diagnostic context, the drug is administered as a continuous peripheral intravenous infusion at a fixed rate of 0.14 mg/kg/min for a total duration of six minutes.

---

Population-Specific Use

Pediatric Use: The official label specifies a weight-based regimen for the acute termination of PSVT. The starting bolus is 0.1 mg/kg (maximum initial dose of 6 mg), with subsequent increments of 0.1 mg/kg if required, up to a maximum total dose of 12 mg.

Research evidence / Overview of Studies for Adenocor

Evidence for Use in Acute Paroxysmal Supraventricular Tachycardia (PSVT)

Research has primarily focused on the use of Adenocor in conditions associated with acute or disruptive episodes, specifically Paroxysmal Supraventricular Tachycardia (PSVT). Scientists have conducted rigorous Randomized Controlled Trials (RCTs) to explore the outcomes of its application in patients experiencing these sudden, fast heart rhythms. The findings from these individual trials are often collected and summarized in comprehensive Systematic Reviews and Meta-analyses.

The studies monitored specific outcomes describing episodic or acute changes. Researchers primarily measured the rate of heart rhythm restoration back to a normal sinus pattern. They also monitored the very short time interval required to measure this change following administration. The resulting findings describe patterns observed in the studies over these defined time intervals. The overall certainty of this evidence is often classified by reviewers as moderate.

Evidence for Use as a Diagnostic Tool

Adenocor was evaluated in research exploring the assessment of its application as an aid to diagnosis for patients presenting with certain fast heart rhythms of uncertain origin. This research often involves observational cohort studies and clinical series. The main outcome examined was whether a temporary change in the heart’s electrical activity was intended to help healthcare professionals assess the underlying rhythm diagnosis. The findings described patterns related to the effect and its measurement in the specific study settings. However, the evidence is largely based on smaller study populations, and the certainty remains low compared to the main therapeutic indication.

Long-Term Research and Follow-up Durations

It is important to note that follow-up durations were limited. The research focus is necessarily on the immediate change in the heart's electrical system, which dictates the short duration of the observed effect. There is limited information for long-term outcomes regarding the health status of patients or the long-term recurrence rates of the heart rhythm problem. Existing studies provide limited insight into the durability of the observed response beyond the immediate post-treatment observation period.

Evidence in Special Populations

Research has explored the use of Adenocor in specific patient groups where evidence is often less comprehensive. For instance, its use in pediatric patients (including infants and children) was observed in open-label studies and clinical experience that regulators have reviewed. While older adults were included in some RCTs, data for certain groups remain insufficient for a detailed subgroup analysis across the entire evidence base. The evidence highlights that results apply only to the populations studied, and research does not determine whether an individual will respond similarly.

Study Gaps and Evidence Uncertainty

Scientific literature points to several areas where research remains limited or uncertain. Evidence quality varies across studies, and many older therapeutic trials lacked blinding. Patient-reported outcomes describing the subjective experience during the acute treatment are not fully established or well-characterized in much of the controlled literature. Data are still emerging for certain treatment parameters, and research is ongoing in several areas.

Key Studies & References

1. Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia (Cochrane Review)
2. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia (SVT)
3. Public Assessment Report for paediatric studies: ADENOSINE (European Regulatory Document)

How to Store and Dispose of Adenocor (Adenosine Injection)

The storage and disposal of Adenocor are governed by specific regulatory requirements to maintain product stability and ensure safe handling.

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature, 20 to 25C (68 to 77F).
Light Protection	Keep the vials stored protected from light in the original container.
Prohibited	Do not refrigerate. Refrigeration may cause the solution to crystallize. If crystals appear, the solution must be warmed to room temperature to dissolve them, and must be clear prior to use.

Disposal Instructions

Adenocor is a preservative-free, single-dose product. The unused portion of the vial must be immediately discarded after use. Disposal of the medicine must be carried out in accordance with local pharmaceutical waste regulations and should not be placed into household waste or wastewater. The product must also be stored out of the sight and reach of children.